한국형 양극성 장애 약물치료 알고리듬 2022: 혼재성 양상
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김원 | - |
dc.contributor.author | 박원명 | - |
dc.contributor.author | 우영섭 | - |
dc.contributor.author | 정종현 | - |
dc.contributor.author | 서정석 | - |
dc.contributor.author | 추일한 | - |
dc.contributor.author | 양찬모 | - |
dc.contributor.author | 이정구 | - |
dc.contributor.author | 심세훈 | - |
dc.contributor.author | 윤보현 | - |
dc.contributor.author | 박성용 | - |
dc.contributor.author | 손인기 | - |
dc.contributor.author | 김문두 | - |
dc.contributor.author | 정명훈 | - |
dc.contributor.author | 전덕인 | - |
dc.date.accessioned | 2023-03-08T07:15:48Z | - |
dc.date.available | 2023-03-08T07:15:48Z | - |
dc.date.issued | 2022-05 | - |
dc.identifier.issn | 1015-4817 | - |
dc.identifier.issn | 2289-0963 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/61344 | - |
dc.description.abstract | Objectives Treatment guidelines or an algorithm can help clinicians implement better practices and clinical decisions. Therefore, the Korean Medication Algorithm Project for Bipolar Disorder 2022 (KMAP-BP 2022) was revised again through a consensus of expert opinion. The diagnosis and treatment of mixed features are not simple, and there are many things to discuss. We describe the preferences and recommendations from KMAP-BP 2022 for the treatment of mood episodes with mixed features. Methods We revised the KMAP-BP 2018 questionnaire and conducted the survey with expert clinicians. Out of ninety-three members of the review committee, eighty-seven completed the survey. We analyzed the answers, discussed the data, and held a clinician hearing. Results In first-step strategies for mixed features with more manic symptoms, a combination of a mood stabilizer and an atypical antipsychotic is the treatment of choice. Mood stabilizer monotherapy and atypical antipsychotic monotherapy are preferred strategies. For mixed features with more depressive symptoms, a combination of mood stabilizer and atypical antipsychotic, a combination of atypical antipsychotic and lamotrigine (LMT), atypical antipsychotic monotherapy, a combination of mood stabilizer and LMT, and mood stabilizer monotherapy are preferred. For mixed features with similar manic symptoms and depressive symptoms, a combination of mood stabilizer and atypical antipsychotic, atypical antipsychotic monotherapy, and mood stabilizer monotherapy are preferred. Conclusion For mixed features, a combination of mood stabilizer and atypical antipsychotic is generally preferred, and LMT is preferred for depressive symptoms. Compared with KMAP-BP 2018, more diverse strategies and drugs are being attempted for the treatment of mixed features. | - |
dc.format.extent | 10 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.publisher | 대한신경정신의학회 | - |
dc.title | 한국형 양극성 장애 약물치료 알고리듬 2022: 혼재성 양상 | - |
dc.title.alternative | Korean Medication Algorithm Project for Bipolar Disorder 2022: Mixed Features | - |
dc.type | Article | - |
dc.identifier.doi | 10.4306/jknpa.2022.61.2.133 | - |
dc.identifier.bibliographicCitation | 신경정신의학, v.61, no.2, pp 133 - 142 | - |
dc.identifier.kciid | ART002843395 | - |
dc.description.isOpenAccess | Y | - |
dc.citation.endPage | 142 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 133 | - |
dc.citation.title | 신경정신의학 | - |
dc.citation.volume | 61 | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Bipolar disorder | - |
dc.subject.keywordAuthor | KMAP-BP 2022 | - |
dc.subject.keywordAuthor | Pharmacotherapy | - |
dc.subject.keywordAuthor | Mixed features | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.